Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) ...

HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma ...

The IAEA has released comprehensive guidance on dose management systems — software tools that collect, monitor and analyse patient data on radiation doses. This new resource will help medical ...

Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...

In this study, luvelta demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer across all levels of Folate Receptor-α (FRα) expression of 25% or greater, including an ...

Despite their growing use in routine clinical practice, guidance on how to set up, evaluate, and ensure the accuracy of these ...

Please provide your email address to receive an email when new articles are posted on . Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile ...

The radiation dose management (RDM) market is undergoing a period of significant expansion, fueled by multiple converging ...

Historically, anticancer drugs have been developed and approved for marketing on the basis of the assumption that the optimal dose is the maximum tolerated dose (MTD). That paradigm was well-suited ...